Kinetics of early peanut allergy development and resolution in the EAT, LEAP, and PAS cohorts

Background: Little is known about the development and resolution of early peanut allergy (PA). Objective: We examined the natural history and biomarkers of PA longitudinally in 3 cohorts. Methods: PA development was examined in the Enquiring About Tolerance (EAT), Learning Early About Peanut (LEAP), and Peanut Allergy Sensitization (PAS) cohorts. Early PA was defined by […]

The kinetics of epitope-specific IgE and IgG4 in early peanut allergy development and resolution

Background: The development and resolution of peanut allergy (PA) was evaluated in children enrolled or screened for the LEAP intervention trial. The development of epitope-specific-immunoglobulin(es-Ig)E and es-IgG4 antibodies was evaluated in a subset of these children to determine whether their PA status could be predicted at 4-11 months of age. Methods: Sera from 386children enrolled […]

Peanut challenges prior to oral immunotherapy demonstrate high tolerance rates in selected patients

Background: Peanut oral immunotherapy (pOIT) protocols typically remain below the threshold for reaction during the initial dose escalation (IDE) day. However, some patients may have higher thresholds for reaction or may not have an ongoing peanut allergy. Objective: We sought to characterize the response to an accelerated initial dose escalation (A-IDE) for qualifying low-risk peanut-allergic […]

Ara h 2-expressing cucumber mosaic virus-like particle (VLP Peanut) induces in vitro tolerogenic cellular responses in peanut-allergic individuals

Background: Peanut allergy (PA) is one of the most prevalent food allergies with a lack of favorable safety/efficacy treatment. A cucumber mosaic virus-like particle expressing peanut allergen component Ara h 2 (VLP Peanut) has been developed as a novel therapeutic approach for PA. Objective: We assessed the tolerogenic properties and reactivity of VLP Peanut. Methods: […]

Air pollution is associated with persistent peanut allergy in the first 10 years

Background: The role of air pollution in eczema and food allergy development remains understudied. Objective: We aimed to assess whether exposure to air pollution is associated with eczema and food allergies in the first 10 years of life. Methods: HealthNuts recruited a population-based sample of 1-year-old infants who were followed up at ages 4, 6, […]

Saliva antibody profiles are associated with reaction threshold and severity of peanut allergic reactions

Background: Reaction threshold and severity in food allergy are difficult to predict, and there is a lack of non-invasive predictors. Objectives: We sought to determine the relationships between pre-challenge levels of peanut (PN)-specific antibodies in saliva and reaction threshold, severity, and organ-specific symptoms during peanut allergic reactions. Methods: We measured PN-specific antibody levels in saliva […]

Desensitization and remission after peanut sublingual immunotherapy in 1- to 4-year-old peanut-allergic children: A randomized, placebo-controlled trial

Background: Prior studies of peanut sublingual immunotherapy (SLIT) have suggested a potential advantage with younger age at treatment initiation. Objective: We studied the safety and efficacy of SLIT for peanut allergy in 1- to 4-year-old children. Methods: Peanut-allergic 1- to 4-year-old children were randomized to receive 4 mg peanut SLIT versus placebo. Desensitization was assessed […]

Defining the window of opportunity and target populations to prevent peanut allergy.

Background: Peanut allergy affects 1% to 2% of European children. Early introduction of peanut into the diet reduces allergy in high-risk infants. Objective: We aimed to determine the optimal target populations and timing of introduction of peanut products to prevent peanut allergy in the general population. Methods: Data from the Enquiring About Tolerance (EAT; n = 1303; […]